Betaxolol attenuates retinal ischemia/reperfusion damage in the rat

NeuroReport

Volumn 14, Issue 15, 2003, Pages 1913-1917

  Cheon, Eun Woo ^a,c   Park, Chang Hwan ^a   Kang, Sang Soo ^a   Cho, Gyeong Jae ^a   Yoo, Ji Myong ^b   Song, Joon Kyung ^b   Choi, Wan Sung ^a  

^a Gyeongsang National University   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Jinju International University   (South Korea)

Author keywords

Betaxolol; Choline acetyltransferase; Intraocular pressure; Ischemia; Protection; Rat; Reperfusion; Retina

Indexed keywords

BETAXOLOL; CHOLINE ACETYLTRANSFERASE; NEUROPROTECTIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CONTROLLED STUDY; IMMUNOREACTIVITY; MALE; MORPHOMETRICS; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RETINA BLOOD FLOW; RETINA ISCHEMIA; TREATMENT OUTCOME; ANIMAL; DRUG EFFECT; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETINA; RETINA DEGENERATION; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETAXOLOL; CHOLINE O-ACETYLTRANSFERASE; IMMUNOHISTOCHEMISTRY; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; RETINA; RETINAL DEGENERATION;

EID: 0642339282     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200310270-00006     Document Type: Article

References (22)

1. Bresnick GH. Arch Ophthalmol 107, 339-341 (1989).
2. Ankarcrona M, Dypbukt JM, Bonfoco E et al. Neuron 15, 961-973 (1995).
3. Delbarre G, Delbarre B, Calinon F, Ferger A. J Ocul Pharmacol 7, 147-155 (1991).
4. Neal MJ, Cunningham JR, Hutson PH, Hogg J. J Neurochem 62, 1025-1033 (1994).
5. Louzada-Junior P, Dias JJ, Santos WF et al. J Neurochem 59, 358-363 (1992).
6. Adachi K, Kashii S, Masai H et al. Graefes Arch Clin Exp Ophthalmol 236, 766-774 (1998).
7. Choi DW. Trends Neurosci 11, 465-469 (1988).
8. Ferreire IL, Duarte CB, Carvalho AP. Eur J Pharmacol 302, 153-162 (1996).
9. Orrenius S, Nicotera P. J Neural Transm 43, 1-11 (1994).
10. Setoguchi M, Ohya Y, Abe I, Fujishima M. Br J Pharmacol 115, 198-202 (1995).
11. Alward WL. New Engl J Med 339, 1298-1307 (1998).
12. Hoste AM, Sys SU. J Cardiovasc Pharmacol 32, 390-396 (1998).
13. Osborne NN, Cazevieille C, Carvalho AL et al. Brain Res 751, 113-123 (1997).
14. Morrison JC, Nylander KB, Lauer AK et al. Invest Ophthalmol Vis Sci 39, 526-531 (1998).
15. Osborne NN, DeSantis L, Bae JH et al. Exp Eye Res 69, 331-342 (1999).
16. Wood JPM, DeSantis L, Chao HM, Osborne NN. Exp Eye Res 72, 79-86 (2001).
17. Cheon EW, Kim YH, Cho YY et al. Exp Eye Res 75, 591-601 (2002).
18. Takahashi K, Lam TT, Edward DP et al. Arch Ophthalmol 110, 862-870 (1992).
19. Osborne NN, Ugarte M, Chao M et al. Surv Ophthalmol 43(suppl 1), S102-S128 (1999).
20. Baptiste DC, Hartwick ATE, Jollimore CAB et al. Invest Ophthalmol Vis Sci 43, 2666-2676 (2002).
21. Hirooka K, Kelly MEM, Baldridge WH, Barnes S. Exp Eye Res 70, 611-621 (2000).
22. Szabo ME, Droy-Lefaix MT, Doly M et al. Invest Ophthalmol Vis Sci 32, 1471-1478 (1991).